Salisbury, UK, 11th September 2012: NanoSight, leading manufacturers of unique nanoparticle characterization technology, have added syringe pump capabilities to their family of nanoparticle characterization systems.
Always looking for ways to enhance the capabilities of their Nanoparticle Tracking Ananlysis (NTA) systems, NanoSight announces the addition of a syringe pump to its range of accessories. This is available for use with all models of NTA systems, meaning even the oldest users may enjoy the benefits of upgrading. Enhancing reproducibility of sizing and counting data and combating photobleaching when using fluorophore labels underscores the reliability of NTA as one of the most used nanoparticle characterization systems today.
Improving measurement repeatability is always most important to analysts. The syringe pump allows an increased number of sample particles that are detected and tracked during an analysis. This gives a more representative sample population and increases the repeatability of the size distribution results, especially for polydisperse samples. It also improves the repeatability of concentration measurements, by continually introducing fresh sample volumes during analysis. This, in combination with the SCRIPT batch analysis procedure, ensures consistent standard operation procedures for the most accurate and reproducible concentration measurements, especially for counting larger particles and aggregates.
Furthermore, increasing the sampling population allows for more accurate analysis of extremely dilute systems, which would otherwise require extremely long capture durations to detect and track sufficient particles for statistically robust measurements.
Using the syringe pump reduces the photo-bleaching effect seen by fluorescent nanoparticles illuminated by the laser beam under static flow conditions. Flowing fluorescently labelled samples through the beam reduces the time each particle is being illuminated by the laser and is therefore highly recommended for fluorescent labelling studies. A fresh population of un-bleached nanoparticles is continually introduced into the instrument field of view, giving improved statistics for fluorescence measurements.
Speaking about the new capability for NTA, NanoSight Head of Development, Dr Patrick Hole, says “the syringe pump has greatly increased the performance of our NTA systems and meets the requests from our users worldwide who have been asking for better reproducibility as they have come to rely upon NTA as their “go to” test method when sizing and counting their nanoparticles.”
To find out about the company and to learn more about particle characterization using NanoSight’s unique Nanoparticle Tracking Analysis solutions, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company’s electronic newsletter.
About NanoSight:
NanoSight delivers the world’s most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight’s “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.
This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.
NanoSight has installed more than 500 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight’s technology is validated by 500+ third party papers citing NanoSight results and by the ASTM Standard E2834, consolidating NanoSight’s leadership position in nanoparticle characterization. For more information, visit www.nanosight.com
For further information:
Please contact NanoSight direct or their marketing agency, Talking Science:
NanoSight Limited
Minton Park
London Road
Amesbury SP4 7RT UK
T +44(0)1980 676060
F +44(0)1980 624703
www.nanosight.com
jeremy.warren@nanosight.com
Talking Science Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA UK
T +44(0)1799 521881
M +44(0)7843 012997
www.talking-science.com
jezz@talking-science.com
